San Diego-based mostly Viking Therapeutics marked by itself as a significant competitor while in the weight loss drug market in February after revealing promising data from a mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified as being a weekly injection and in March the co